Radiotherapy using IMRT boosts after hyperbaric oxygen therapy with chemotherapy for glioblastoma. (18th November 2016)

• Record Type: Journal Article
• Authors: Yahara, Katsuya; Ohguri, Takayuki; Udono, Hiroki; Yamamoto, Junkoh; Tomura, Kyosuke; Onoda, Toshihiro; Imada, Hajime; Nishizawa, Shigeru; Korogi, Yukunori
• Is Part Of: Journal of radiation research. Volume 58:Number 3(2017:May)
• Page Start: 351
• Page End: 356
• Publication Date: 2016-11-18
• Subjects: glioblastoma -- hyperbaric oxygen -- intensity-modulated radiotherapy -- high-grade glioma -- radiosensitization; Radiology, Medical -- Periodicals; Radiobiology -- Periodicals; Radiation -- Periodicals; 616.0757
• DOI: 10.1093/jrr/rrw105
• Languages: English
• ISSNs: 0449-3060

Abstract

Abstract: The purpose of this study was to evaluate the feasibility and efficacy of radiotherapy (RT) using intensity-modulated radiotherapy (IMRT) boosts after hyperbaric oxygen (HBO) therapy with chemotherapy in patients with glioblastoma. Twenty-four patients with glioblastoma were treated with the combined therapy, which was RT using IMRT boosts after HBO with chemotherapy, and were retrospectively analyzed. The RT protocol was as follows: first, 3D conformal RT [40 Gy/20 fractions (fr)] was delivered to the gross tumor volume (GTV) and the surrounding edema, including an additional 1.5–2.0 cm. The IMRT boost doses were then continuously delivered to the GTV plus 5 mm (28 Gy/8 fr) and the surrounding edema (16 Gy/8 fr). Each IMRT boost session was performed immediately after HBO to achieve radiosensitization. The planned RT dose was completed in all patients, while HBO therapy was terminated in one patient (4%) due to Grade 2 aural pain. The toxicities were mild, no non-hematological toxicity of Grade 3–5 was observed. The 2-year overall survival (OS) and progression-free survival rates in all patients were 46.5% and 35.4%, respectively. The median OS time was 22.1 months. In conclusion, the combined therapy of RT using IMRT boosts after HBO with chemotherapy was a feasible and promising treatment modality for patients with glioblastoma. The results justify further evaluation to clarify the benefits of this therapy.